Form 4: Richard Heyman Sells Oric Pharmaceuticals Stock

Director Richard Heyman reported a sale of 41,800 shares of Oric Pharmaceuticals common stock on July 6, 2026, pursuant to a Rule 10b5-1 trading plan.

Summary

• Richard A. Heyman, a Director at Oric Pharmaceuticals, Inc., reported a transaction on July 6, 2026.
• The transaction involved the disposition of 41,800 shares of common stock.
• The sale was executed under a Rule 10b5-1 trading plan established by Mr. Heyman and RAHD Capital, LLC.
• Following the transaction, Mr. Heyman beneficially owns 212,772 shares of common stock, with 300 shares held directly and the remainder indirectly through RAHD Capital, LLC.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the insider sale, although it was conducted under a pre-arranged trading plan.

Negatives

• Director Richard Heyman sold a significant number of shares (41,800) of Oric Pharmaceuticals common stock.

Future Outlook

The filing does not contain any forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider sales, especially under Rule 10b5-1 plans, are common for portfolio management but can sometimes be interpreted by the market as a lack of confidence, depending on the scale and context of the sale relative to the insider's total holdings.

Stakeholder Impact

• Shareholders may view the sale by a director as a potential signal, although the Rule 10b5-1 plan mitigates concerns about opportunistic trading.

Key Dates

Keywords

Oric Pharmaceuticals, SEC Form 4, Insider Trading, Stock Sale, Rule 10b5-1, Director Transaction, Beneficial Ownership